The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus. 2008

Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
Third Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan. kazukun@jg7.so-net.jp

The aim of this study was to evaluate the effect of pioglitazone on nitric oxide in patients with type 2 diabetes and coronary artery disease. Twenty-seven patients with coronary artery disease and diabetes mellitus who had received coronary stenting were eligible for the study. They were assigned to the no insulin resistance (NIR) group, the insulin resistance (IR) group, and the pioglitazone group (30 mg once a day). Endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha), interleukin-6, leptin, and adiponectin were measured. In the pioglitazone group, eNOS, iNOS, and leptin were significantly lower and adiponectin was significantly higher than those in the IR group. Stepwise multiple regression analyses showed that eNOS correlated with TNF-alpha and iNOS correlated with leptin and TNF-alpha. Leptin was the strongest predictor of iNOS. Treatment with pioglitazone significantly reduced eNOS and iNOS by improving adipocytokine levels.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077205 Pioglitazone A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS. Pioglitazone Hydrochloride,5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione,AD 4833,AD-4833,Actos,U 72107A,U-72107A,U72,107A,AD4833,U72107A
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
November 2006, Atherosclerosis,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
June 2002, Endocrine journal,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
May 2022, European review for medical and pharmacological sciences,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
January 2003, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
August 2010, Journal of clinical pharmacy and therapeutics,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
January 2011, European journal of endocrinology,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
May 2013, Acta histochemica,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
January 2012, Diabetes & metabolic syndrome,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
January 2006, Treatments in endocrinology,
Kazuaki Nishio, and Meiei Shigemitsu, and Yusuke Kodama, and Seiji Itoh, and Noburu Konno, and Ryuji Satoh, and Takashi Katagiri, and Youichi Kobayashi
April 2007, Journal of atherosclerosis and thrombosis,
Copied contents to your clipboard!